STOCK TITAN

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Belite Bio, Inc (BLTE) will host a webcast on March 12, 2024, to discuss financial results and business updates for Q4 and full year 2023, focusing on therapeutics for degenerative retinal diseases.
Positive
  • None.
Negative
  • None.

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, March 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2023.

Webcast Information
Date: Tuesday, March 12, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://wsw.com/webcast/cc/blte2/1419894

Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com


Belite Bio, Inc (BLTE) will host the webcast on Tuesday, March 12, 2024.

The webcast will start at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

The webcast will focus on the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2023.

You can join the live webcast by visiting the provided webcast link or the 'Presentations & Events' section of the Company’s Investor Relations website.

Yes, a replay will be available for approximately 90 days after the event.
Belite Bio Inc

NASDAQ:BLTE

BLTE Rankings

BLTE Latest News

BLTE Stock Data

Medicinal and Botanical Manufacturing
Manufacturing

About BLTE

belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.